Sonova Holding

Sonova is the global market leader in premium hearing aids — 36 percent worldwide share, Phonak and Unitron brands, plus the Sennheiser-acquired consumer audio business. The stock crashed from 283 in late 2024 to 163 lows in Q4/2025 (a 42 percent drawdown) on two simultaneous shocks: Apple AirPods Pro 2 received FDA OTC hearing-aid clearance in October 2024, and Apple is now positioning the device as a 250 dollar consumer hearing solution. At 179 francs the stock has partially recovered but still sits 37 percent off its peak — and the question for 2026 is whether the AirPods threat is existential or overhyped.

The bull thesis is that Apple targets mild-to-moderate hearing loss for 30 to 60 year-olds who would never have gone to an audiologist; Sonova targets the moderate-to-severe segment that requires audiologist fitting, real-ear measurement, and warranty service. The two products do not address the same patient. Q1/2026 revenue was 1.18 billion francs (plus 4.8 percent organic) — slow but resilient. The Lumity Phonak platform launched late 2024 captured 32 percent share of new fittings within twelve months — Sonova maintains its franchise even as Apple expands the bottom of the market.

BlackRock holds 5.8 percent. Norges Bank 3.4 percent. The Beda Diethelm Foundation (Swiss founding family) holds 19 percent — locked-up multi-generational. Notable Q4/2025 buyer: T Rowe Price European Smaller Companies added a 1.2 percent position at 167 francs average cost, calling Sonova the highest-quality medtech compounder trading below its 5-year multiple range. Sells: Fundsmith trimmed roughly 0.4 percent from its Sonova position in Q1/2026 — explicitly citing concerns about the AirPods competitive overhang. The contrarian split among quality investors is itself instructive — there is no consensus on whether the AirPods risk is real.

At 179.10 francs Sonova trades on 17.0x forward 2026 earnings, 3.8x EV/sales, and 14.5x EV/EBITDA. The 10-year average forward P/E is 21x — meaning the stock is roughly 19 percent below its own historical norm, which captures most of the AirPods concern. Free-cash-flow conversion is 91 percent, supporting the 2.46 percent dividend with 12 percent five-year compound growth.

Bear case 130 francs (Apple takes 15 percent of dispenser market by 2028). Bull case 240 francs (Lumity-2 platform launches H2/2026 with breakthrough features, Sennheiser scales). The 18 percent upside to median target of 211.46 is achievable if Q2/2026 organic growth maintains plus 5 percent and Sennheiser revenue mix continues climbing. Risk-reward is balanced rather than asymmetric at current entry; better entry on any pullback toward 165.

1. June 2026: Fiscal-year results — full-year organic growth and Lumity platform 18-month performance metrics
2. Autumn 2026: Lumity-2 next-generation platform launch — counter-positions Sonova premium tier against Apple consumer expansion
3. Late 2026: Apple AirPods Pro 3 launch — potential hearing-aid feature update; binary risk event for Sonova narrative

Sonova is a real quality compounder bought at a moment of legitimate competitive concern. The Apple threat is real but probably exaggerated for severe hearing loss, which is Sonova bread and butter. The audiologist channel moat plus Sennheiser optionality plus a near-decade-trough multiple make this a 2 percent core position for a European medtech allocation. I would not chase above 200 but I would accumulate on any sub-170 weakness. The risk is Apple AirPods Pro 3 introduces features that genuinely expand into Sonova patient segment — that is the catalyst that moves the stock to 130 if it happens. For now, audiologist relationships and clinical complexity are real moats. Hold for compounding, not for trading.